Published in
American Association for the Advancement of Science, Science Translational Medicine, 450(10), 2018
DOI: 10.1126/scitranslmed.aar3342
Links
Tools
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Journal article published in 2018 by
Scott J. Rodig 
,
Jason L. Weirather ,
Jedd D. Wolchok ,
Daniel Gusenleitner ,
Donald G. Jackson,
Evisa Gjini,
Anita Giobbie-Hurder,
Chelsea Jin ,
Han Chang,
Scott B. Lovitch ,
Christine Horak,
Michael A. Postow,
Jeffrey S. Weber ,
Anna C. Pavlick ,
Jason Chesney
and other authors.
,
Jason L. Weirather ,
Jedd D. Wolchok ,
Daniel Gusenleitner ,
Donald G. Jackson,
Evisa Gjini,
Anita Giobbie-Hurder,
Chelsea Jin ,
Han Chang,
Scott B. Lovitch ,
Christine Horak,
Michael A. Postow,
Jeffrey S. Weber ,
Anna C. Pavlick ,
Jason Chesney
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.